Bayer (ETR:BAYN) said Monday it won FDA premarket approval for its Betaconnect electronic autoinjector for treating relapsing-remitting multiple sclerosis patients on the drug Betaseron.
The Betaconnect is the 1st and only electronic autoinjector if its kind to treat RRMS, Whippany, N.J.-based Bayer said.
“Bayer has a long legacy of supporting and providing services for the RRMS community. Betasaron was the 1st disease-modifying therapy approved by the FDA to treat RRMS patients, and today we are pleased to offer the 1st and only electronic auto injector for those living with the disease,” Bayer neurology veep Klaus Marten said in prepared remarks.
The Betaconnect device allows for customizable injection speed and depth settings, and comes with an optional back-up reminder to inform patients when its time for their next injection. The device also comes with visual and audio end-of-dose indications, as the needle injection and retraction are automatic, the company said.
“Offering new options to individuals with MS to help manage their disease is important since ‘1 size does not fit all’ when considering MS treatment,” Multiple Sclerosis Association of America CEO Douglas Franklin said in a press release.
The Betaconnect device will be available for Betasaron patients beginning in early 2016, Bayer said.
The post Bayer wins PMA for Betaconnect electronic autoinjector appeared first on MassDevice.
from MassDevice http://ift.tt/1P7vn5K
Cap comentari:
Publica un comentari a l'entrada